Billion-Dollar Molecules: Etavopivat, an Allosteric PKR Kinase Activator for Sickle Cell Disease
Abstract. Novo Nordisk has acquired Forma Therapeutics for $1.1B for its primary investigational drug, etavopivat. Etavopivat, a past Molecule of the Month, is an oral, once-daily allosteric activator of pyruvate kinase-R (PKR), which is currently being tested in Phase II/III clinical trials for the treatment of sickle cell disease and other hemoglobinopathies. In this article, we cover:
- the mechanism of action of the drug
- the clinical context of the acquired portfolio
- the details of the deal
request a trial
Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more.
Interested in learning more? Submit this form to request a trial.
